Glecirasib

Glecirasib (JAB-21822) is Jacobio Pharmaceuticals' selective covalent KRAS G12C inhibitor. NMPA granted conditional approval in China in August 2024 for previously treated KRAS G12C-mutated advanced non-small cell lung cancer based on a 47.9% ORR Phase 2b dataset (NCT05002270) [1]. Phase 3 confirmatory work and Phase 1/2 expansion trials are ongoing in China, including a combination with sitneprotafib (JAB-3312), an inhibitor of SHP2 (an enzyme that helps reactivate RAS signaling via receptor tyrosine kinases and is a known resistance pathway), which posted 60% ORR in TKI-naive (patients not previously treated with targeted kinase inhibitor therapy) NSCLC patients [2], plus combinations with cetuximab in KRAS G12C-mutated colorectal cancer [3]. The commercial question is whether a Chinese biotech can carve out meaningful share in a KRAS G12C class already dominated by Amgen's sotorasib and BMS/Mirati's adagrasib, while Revolution Medicines' pan-RAS daraxonrasib redefines the broader RAS market with strong OS data in pancreatic cancer [4].

Glecirasib is a novel compound, not a repurposed drug. Lead indication is second-line KRAS G12C-mutated NSCLC, where NMPA granted conditional approval in August 2024 based on the Phase 2b study (n=119) showing 47.9% objective response rate and 8.2-month median progression-free survival [1]. Confirmatory Phase 3 work in NSCLC and additional Phase 1/2 trials in colorectal and pancreatic cancer continue under Jacobio sponsorship and Allist Pharmaceuticals as China partner [5][6]. The Phase 3 design (enrollment target, comparator arm, primary endpoint) has not been publicly disclosed in trial registries reviewable as of mid-2026, so the path from conditional to full NMPA approval is opaque. China NRDL (National Reimbursement Drug List) status is the primary commercial gating event for Chinese revenue: NRDL inclusion determines whether patients can access the drug affordably and whether hospitals stock it. We have not seen public disclosure that glecirasib has been included in or formally submitted to NRDL negotiations; for Chinese conditional approvals the typical window to first NRDL submission is 12 to 24 months post-approval. FDA designations for glecirasib in the United States have not been publicly disclosed; Jacobio has not filed for US approval as of mid-2026, has not disclosed any ex-China licensing agreement, and has not announced FDA or EMA scientific advice meetings, so the development path outside China remains unclear. The Lancet Respiratory Medicine combination trial with sitneprotafib (JAB-3312, a SHP2 inhibitor) reported 60% ORR in TKI-naive patients in early 2026, supporting a combination strategy [2]. Pooled Phase 1/2 data across solid tumors published in Cancer Communications (2025) reported manageable toxicity and meaningful activity, with cetuximab combination data in CRC subsequently published in Lancet Gastroenterology & Hepatology in 2026 [3][7]. Next catalysts: confirmatory Phase 3 NSCLC data, NRDL inclusion announcement, and pancreatic cancer expansion (NCT06008288, n=88, recruiting) [6].

KRAS is a protein that works like an ignition switch for cell growth. Normal KRAS toggles between an 'on' state bound to GTP and an 'off' state bound to GDP. The G12C mutation swaps a glycine for cysteine at position 12 and biases the switch toward 'on,' driving uncontrolled proliferation in roughly 13% of non-small cell lung cancers and 3-4% of colorectal cancers [8]. Glecirasib is a covalent inhibitor: it forms an irreversible chemical bond with that exposed cysteine while KRAS sits in its inactive GDP-bound state, trapping it there and preventing further signaling. This is the same mechanistic playbook that produced sotorasib (Amgen, FDA approved 2021) and adagrasib (Mirati/BMS, FDA approved 2022) [9][10], so the target is genetically and pharmacologically validated. The differentiation argument for glecirasib rests on pharmacokinetic profile and combinability rather than novelty of mechanism. Published intracranial activity data for glecirasib is limited, so any claim of CNS exposure advantage versus adagrasib (which has documented intracranial response data and uses it as a commercial selling point) is not yet supported by disclosed evidence. The combination with sitneprotafib (a SHP2 inhibitor) addresses a known resistance pathway: even when G12C-mutant KRAS is locked off, tumors can route around the blockade by activating wild-type RAS through upstream receptor tyrosine kinase signaling, and SHP2 sits squarely in that reactivation circuit. SHP2 inhibition closes that escape hatch, at least in early data [2].

The registrational NSCLC dataset (NCT05002270, Phase 2b) enrolled 119 patients with previously treated KRAS G12C-mutated advanced NSCLC across 35 Chinese sites. Primary endpoint was confirmed objective response rate by independent review (47.9%), with median PFS of 8.2 months and disease control rate of 86.6% [1]. The design is single-arm, which is conventional for second-line oncology accelerated approval pathways but limits direct comparison to sotorasib (CodeBreaK 200 Phase 3 head-to-head vs docetaxel, 6.3-month PFS in the sotorasib arm) and adagrasib (KRYSTAL-1, approximately 6.5-month PFS) [9][10]. Direct numerical comparison is inappropriate: population differences (prior therapy lines, performance status, geographic patient characteristics, response assessment cadence) make cross-trial PFS comparisons misleading without prospective head-to-head data. The longer PFS reported for glecirasib is a hypothesis worth testing, not a superiority claim. The confirmatory Phase 3 NSCLC trial design has not been publicly disclosed in registries, so the comparator arm, sample size, and primary endpoint are unknown as of mid-2026. NCT06008288 (Phase 2 monotherapy in pancreatic cancer and other solid tumors, n=88, sponsored by Allist Pharmaceuticals) targets ORR by central review per RECIST 1.1 (a standardized tumor measurement system used to define response in solid tumor trials) and is recruiting [6]. The sitneprotafib combination trial reported in Lancet Respir Med targets the TKI-naive first-line setting where the bar is higher: chemo-immunotherapy combinations already deliver substantial ORR and durable PFS, so glecirasib plus sitneprotafib needs to clear that without additive toxicity [2]. Enrollment in China appears healthy; ex-China Phase 3 capacity has not been publicly disclosed.

Our model estimates a 75% chance this drug is eventually approved. It starts from the historical base rate for filing drugs in this area (about 84%), then adjusts using ten facts about the trial and sponsor. What moves the number most: it is helped by a non-randomized design and its light or open-label blinding; it is held back by the sponsor's thin or weak approval record and weak or limited earlier-phase results. The other facts land near average for this stage, so they leave the estimate roughly where the base rate put it.

Efficacy risk is moderate. The Phase 2b NSCLC dataset is strong for a single-arm Chinese cohort, but cross-trial comparison with sotorasib and adagrasib has the usual confounds: patient selection, prior-treatment heterogeneity, response assessment cadence. The sitneprotafib combination needs to show that adding SHP2 inhibition delivers a clear PFS or OS benefit over glecirasib alone, not just a higher ORR; combination toxicity (rash, diarrhea, transaminitis, meaning liver enzyme elevations that signal drug-related liver stress) compounds across both agents and may force dose reductions [2]. Safety risk for monotherapy looks tolerable based on published data, with the typical class profile (GI toxicity, hepatic enzyme elevation, fatigue) and no disclosed signal of the QT prolongation (a heart rhythm abnormality that can cause sudden cardiac death) that complicated adagrasib's label, where it carries cardiac monitoring requirements and restrictions on co-administration with other QT-prolonging or strong CYP3A4-modulating drugs [1][10]. Execution risk is the real concern: Jacobio has limited global commercialization infrastructure, no disclosed US partner, and a development plan that looks China-centric. Even strong data may struggle to translate into ex-China revenue without licensing. Commercial risk comes from two sides. Above: Revolution Medicines' daraxonrasib RASolute 302 result (per ASCO 2026 presentation, reported substantial OS benefit versus comparator in metastatic pancreatic adenocarcinoma, with specific median OS and hazard ratio figures subject to final peer-reviewed publication) shifted clinician and payer attention toward pan-RAS RAS(ON) inhibitors [4]. Below: divarasib (Genentech, Phase 3) and Chinese-domestic competitors are converging on the same NSCLC niche, and sotorasib's revenue has tracked below early consensus expectations [11].

Worth watching, but more as a Chinese pharma signal than a global commercial threat. Glecirasib is a credible second- or third-generation KRAS G12C inhibitor with a real NMPA approval and a coherent combination story with sitneprotafib. Signal data points to track: NRDL inclusion (the primary commercial gating event for Chinese revenue), any disclosure of a US registration plan, EMA scientific advice, or ex-China licensing deal. Without those, glecirasib remains a China-asset story trading on Jacobio's local commercial execution. Check back at the next major oncology congress (ESMO 2026, ASCO 2027) for sitneprotafib combination updates and any Phase 3 confirmatory NSCLC data. Jacobio itself (1167.HK) fits the typical Chinese oncology biotech profile: solid scientific output, capital-efficient trials, limited Western dealmaking history. The larger context: the KRAS G12C-selective class is being commercially eclipsed in real time by Revolution Medicines' pan-RAS daraxonrasib, whose RASolute 302 OS data in pancreatic cancer redirected investor capital toward RAS(ON) inhibitors that work across G12D, G12V, and G12C [4][12]. Glecirasib does not solve that problem; nothing G12C-selective does. The bull case is narrow but real: best-in-class G12C ORR/PFS in a market (China NSCLC) where domestic manufacturing and price flexibility matter more than Western marketing infrastructure.